Scope and Claims Analysis for US Patent 10,047,097: Trk-Driven Cancer Treatment Methods Using a Specific (S)-Pyrazolo[1,5-a]pyrimidine Carboxamide Sulfate with Surgery
Executive summary: US 10,047,097 claims method-of-treatment IP built around (i) a specific small-molecule structure specified as the (S) enantiomer and its sulfate salt/solvate, (ii) patient selection by tumor Trk (TrkA/TrkB/TrkC) biomarker status defined as overexpression, activation, amplification, and/or mutation, and (iii) a combination sequencing concept anchored to performing surgery to at least partially resect the tumor and administering the compound either before and/or after the surgery. The estate is claim-scoped primarily around clinical workflow (diagnostic biomarker selection plus peri-operative dosing), with secondary breadth via generic “additional anti-cancer agent” language, dosage-form lists, and broad tumor-type lists spanning multiple solid tumors and CNS malignancies.
What does US 10,047,097 claim: method claims for surgery plus a Trk-targeted small-molecule?
Core active-ingredient identity: what compound is actually claimed
Across independent claims, the “therapeutically effective amount” is limited to:
- (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide sulfate
- and “pharmaceutically acceptable salt or solvate thereof”
This is not a generic “Trk inhibitor” claim. The molecule identity is structural and stereochemical (S at the hydroxypyrrolidine carboxamide stereocenter, and R at the substituted pyrrolidine linkage), plus the specified sulfate form.
Biomarker-driven patient selection is a claim element
Independent claim 1 requires detecting that the cancerous tumor “exhibits one or more of”:
- overexpression
- activation
- amplification
- mutation
of a Trk kinase (with dependent claims specifying TrkA, TrkB, TrkC).
The Trk biomarker language is a gating limitation: use of the compound for a tumor without qualifying Trk status does not fall within the claim as written.
Peri-operative sequencing is a claim element
Independent claim 1 adds a further workflow limitation:
- performing surgery to at least partially resect the tumor
- and administering the compound in a therapeutically effective amount
- with dependent claims specifying sequencing:
- claim 2: surgery before administration
- claim 3: administration before surgery
- claim 4: after surgery, administer the compound again (explicit continuation dosing)
Independent claim 12 is narrower in that it omits the explicit “detecting” step and instead combines:
- administering the compound
- and performing surgery to partially resect the tumor
with sequencing dependent claims 13-15.
Treatment endpoint is not a narrow regimen
Claims are framed as “attenuating or ameliorating one or more symptoms of a cancerous tumor.” That is a standard method-of-treatment endpoint, but it does not narrow to a particular imaging response, survival endpoint, or biomarker reduction. This broad endpoint can capture a wide range of clinically observable improvements.
How broad is US 10,047,097 across tumor types and Trk subtypes?
Trk subtype coverage
Dependent claims cover each Trk family member as qualifying target status:
- claim 6: TrkA
- claim 7: TrkB
- claim 8: TrkC
All are written as “one or more of overexpression, activation amplification, and mutation.” The claim set therefore covers multiple molecular mechanisms by which Trk signaling is enabled.
Tumor-type lists: solid tumor + CNS reach
Claim 11 and claim 22 list tumors (some items are repeated with minor spelling variation). Covered tumors include:
- neuroblastoma
- ovarian
- pancreatic
- colorectal
- prostate
- melanoma
- head and neck cancer
- gastric carcinoma
- lung carcinoma
- breast cancer
- glioblastoma
- medulloblastoma
- secretory breast cancer / secratory breast cancer
- salivary gland cancer
- papillary thyroid carcinoma
This is broad geographies-wise across organ systems, but still finite due to the enumerated list. If a competitor’s label or intended population is outside these named categories, infringement on the enumerated dependent claims becomes harder, though independent claims 1 and 12 still require a “cancerous tumor” exhibiting Trk status and may still sweep beyond the list depending on claim construction of the independent “cancerous tumor” language.
Does the independent claim require the tumor to be on the list?
On the face of the text, independent claims require a “cancerous tumor” with qualifying Trk status, not membership in the enumerated list. Dependent claims 11 and 22 narrow to listed tumors. That creates a tiered landscape:
- must-have: Trk biomarker status + surgery + compound administration
- additional optional narrowing: tumor type enumeration
What combinations are permitted: does US 10,047,097 claim multi-agent chemo, biologics, or targeted antibody add-ons?
Open-ended “one or more agents” clause
Claim 5 (for claim 1) and claim 16 (for claim 12) add breadth by allowing co-administration of “one or more agents” selected from a long class list:
- mitotic inhibitors
- alkylating agents
- antimetabolites
- antisense DNA or RNA
- intercalating antibiotics
- growth factor inhibitors
- signal transduction inhibitors
- cell cycle inhibitors
- enzyme inhibitors
- retinoid receptor modulators
- proteasome inhibitors
- topoisomerase inhibitors
- biological response modifiers
- antihormones
- angiogenesis inhibitors
- targeted antibodies
- HMG-CoA reductase inhibitors
- prenyl-protein transferase inhibitors
This is a classic breadth mechanism: it preserves infringement even if the accused regimen includes standard-of-care therapy platforms, provided the method also includes the claimed surgery + Trk-biomarker selection + compound administration.
How that impacts design-around
A would-be design-around cannot avoid the claim by switching to common chemo or targeted combinations, because the clause explicitly includes a broad menu of classes, including “targeted antibodies” and “growth factor inhibitors.” Avoidance would likely need to attack one of the hard limitations: the claimed compound identity, the Trk biomarker selection step (for claim 1), or the surgery plus sequencing structure.
What is the practical scope of the surgery element in US 10,047,097?
“At least partially resect” is a low barrier
The claims require “performing surgery to at least partially resect the tumor.” That likely covers:
- debulking surgery
- tumor resection
- cytoreductive procedures
It is less likely to require margin-negative resection. It does, however, require that surgery occur as part of the method.
Timing permutations captured
The claim set captures multiple peri-operative scenarios:
- admin after surgery (claim 2 without additional language, but claim 4 explicitly continues post-surgery dosing)
- admin before surgery (claim 3 and corresponding structure in claim 14)
- both pre and post are covered via “before/after” dependent structures (claim 4 and claim 15)
This reduces the ability to avoid infringement by selecting a single temporal approach.
What formulations and dosing forms are covered by US 10,047,097?
Dosage-form coverage is broad but still specific
Claim 9 and claim 20 list dosage forms:
- capsule
- tablet
- solution
- suspension
- syrup
- emulsion
Claim 10 and claim 21 narrow those in dependent form subsets:
- claim 10: capsule, solution, suspension
- claim 21: capsule, solution, suspension
The formulation scope, however, is not a manufacturing method claim. The molecule identity is fixed, so the claim is about how the compound is administered in these forms, not how it is made.
How this affects competition
For infringement risk, if a competitor’s product is not the claimed sulfate salt or a “pharmaceutically acceptable salt or solvate thereof,” it may fall outside the literal scope. If it is within salts/solvates, dosage form changes within the listed categories may still infringe if other elements are met.
Where does US 10,047,097 sit in a broader patent landscape: method claims vs. composition and use claims?
Claim type implications
US 10,047,097 is a method-of-treatment patent. That typically means:
- it is implicated when practicing the claimed clinical method
- it may not be directly circumvented by selling a product unless the product’s use infringes the method claims
Potential overlap with other claim classes in the same molecule family
Without the publication set, assignment map, or related application data, the best operational reading of this patent is as a clinical workflow claim likely intended to complement:
- composition-of-matter (small molecule and/or salt/solvate)
- therapeutic-use claims without surgery
- biomarker selection claims
- combination therapy claims (without the specific surgery element)
Even where composition is already protected, a surgery + biomarker selection method can provide additional leverage in infringement and leverage in settlement, because it ties the molecule to a specific clinical pathway.
What are the claim-by-claim “infringement hooks” and likely litigation targets?
Independent claim 1: highest-sensitivity elements
Claim 1 requires all of:
- detecting a cancerous tumor with Trk biomarker status (overexpression/activation/amplification/mutation)
- administering the specified (S) Trk compound sulfate (or acceptable salt/solvate)
- performing surgery to partially resect the tumor
- sequencing relationships are not explicit in claim 1 but added via dependents (claims 2-4)
Primary infringement hooks:
- the diagnostic/detection step (for claim 1)
- the surgery step
- the exact drug identity
Likely litigation focus in practice:
- whether clinicians “detect” qualifying Trk status
- whether the tumor qualifies as exhibiting the specified Trk alterations
- whether the method includes surgery and compound administration in the required relationship
Dependent claims 2-4: sequencing specificity
- claim 2 locks surgery before administration
- claim 3 locks administration before surgery
- claim 4 adds the post-surgery continuation administration
These are likely to be central if the accused clinical workflow is peri-operative, neoadjuvant, or adjuvant.
Dependent claims 5, 6-8: combination and biomarker subtype
- claim 5 broadens permitted co-therapies
- claims 6-8 specify TrkA/TrkB/TrkC coverage
Dependent claims 9-10: dosage form
These narrow formulation embodiments but likely are satisfied by most oral liquid/solid forms if the compound is used.
Dependent claims 11: tumor type enumeration
This is likely the main “narrowing funnel” limiting certainty of coverage when a competitor targets cancers not in the listed categories.
How strong is US 10,047,097 as an exclusivity barrier?
Strength drivers
- Tight drug identity: fixed stereochemistry and salt identity reduces unrelated prior art overlap for the same compound, but also ensures that only the specific molecule family is implicated.
- Patient selection limitation: Trk biomarker status is a recognized clinical stratifier and can be tested.
- Surgery anchor: adds a real-world procedural element that competitors cannot avoid if their clinical pathway includes resection.
- Sequencing coverage: both pre- and post-surgery administration are captured via dependents.
Strength limiters
- Enumerated tumor lists apply only to dependent claims: if courts treat the independent “cancerous tumor” broadly, the listing may be less limiting; if construed narrowly, it can cap certainty.
- Diagnostic step in claim 1: if an accused method does not include an explicit “detecting” step (or lacks qualifying detection documentation), it may weaken claim 1 but not claim 12.
- Only method claims: enforcement depends on clinical practice, not merely product manufacture or formulation.
What is the Orange Book status and litigation posture of US 10,047,097?
No Orange Book listing, FDA exclusivity ties, P-IV challenges, or litigation documents for US 10,047,097 are provided in the input. Without those records, the status cannot be mapped to regulatory timelines or challenge events.
Key takeaways
- US 10,047,097 claims a method of treating Trk-altered tumors using a specific (S) stereochemical Trk compound sulfate, in combination with tumor surgery (partial resection) and peri-operative dosing.
- The independent claim 1 adds a diagnostic detection element tied to Trk biomarker status (overexpression, activation, amplification, and/or mutation), while independent claim 12 focuses on administration + surgery without requiring the explicit detection step.
- The claim set is broad in permitted co-therapies (multiple chemo and targeted classes) but narrow in the drug identity and partially narrow in tumor types (only on dependent claim paths).
- Sequencing dependents capture neoadjuvant vs adjuvant dosing structures, tightening design-around options.
FAQs
1) Does US 10,047,097 require pre-surgical Trk testing in all cases?
Not if claim 12 is asserted; claim 12 omits the explicit “detecting” step present in claim 1.
2) Can infringement be avoided by using a different Trk inhibitor?
Yes, the claims are limited to the specified (S) compound and its salts/solvates.
3) Are chemotherapy or antibody combinations covered even if the regimen differs from monotherapy?
Yes on the face of claims 5 and 16, which include a broad list of additional agent classes.
4) Does the patent cover both oral and liquid formulations?
Yes, via dependent claims listing capsules/tablets and solutions/suspensions/syrups/emulsions.
5) If a clinician performs surgery but does not administer the compound post-op, is that within the claims?
The core independent structure requires administering the compound as part of the method and performing surgery to partially resect the tumor; sequencing dependents further define timing.
